Deregulated activity of Akt in epithelial basal cells induces spontaneous tumors and heightened sensitivity to skin carcinogenesis

Cancer Research

Volumn 67, Issue 22, 2007, Pages 10879-10888

  Segrelles, Carmen ^a   Lu, Jerry ^b   Hammann, Brian ^b   Santos, Mirentxu ^a   Moral, Marta ^a   Cascallana, José Luis ^c   Lara, M Fernanda ^a   Rho, Okkyung ^b   Carbajal, Steve ^b   Traag, Jeanine ^b   Beltrán, Linda ^b   Martínez Cruz, Ana Belén ^a   García Escudero, Ramón ^a   Lorz, Corina ^a   Ruiz, Sergio ^a,d   Bravo, Ana ^c   Paramio, Jesús M ^a   DiGiovanni, John ^b  

^a CIEMAT   (Spain)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d Salamanca Spain   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; BASAL CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; HISTOPATHOLOGY; IN VIVO STUDY; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOGENESIS; TUMOR;

ANIMALS; CATTLE; EPITHELIUM; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE;

EID: 36348947025     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2564     Document Type: Article

References (41)

1. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004;29:233-42.
2. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochim Biophys Acta 2004;1697:3-16.
3. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005;94:29-86.
4. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62.
5. Bellacosa A, Testa JR, Moore R, Larue L. A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. Cancer Biol Ther 2004;3:268-75.
6. Yang ZZ, Tschopp O, Baudry A, Dummler B, Hynx D, Hemmings BA. Physiological functions of protein kinase B/Akt. Biochem Soc Trans 2004;32:350-4.
7. Wilker E, Lu J, Rho O, Carbajal S, Beltran L, DiGiovanni J. Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-I) skin tumor promotion. Mol Carcinog 2005;44:137-45.
8. Lu J, Rho O, Wilker E, Beltran L, DiGiovanni J. Activation of epidermal Akt by diverse mouse skin tumor promoters. Mol Cancer Res. In press 2007.
9. Segrelles C, Ruiz S, Perez P, et al. Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 2002;21:53-64.
10. Segrelles C, Ruiz S, Santos M, Martinez-Palacio J, Lara MF, Paramio JM. Akt mediates an angiogenic switch in transformed keratinocytes. Carcinogenesis 2004;25:1137-47.
11. Segrelles C, Moral M, Lara MF, et al. Molecular determinants of Akt-induced keratinocyte transformation. Oncogene 2006;25:1174-85.
12. Bol D, Kiguchi K, Beltran L, et al. Severe follicular hyperplasia and spontaneous papilloma formation in transgenic mice expressing the neu oncogene under the control of the bovine keratin 5 promoter. Mol Carcinog 1998;21:2-12.
13. Santos M, Paramio JM, Bravo A, Ramirez A, Jorcano JL. The expression of keratin k10 in the basal layer of the epidermis inhibits cell proliferation and prevents skin tumorigenesis. J Biol Chem 2002;277:19122-30.
14. Naito M, Naito Y, DiGiovanni J. Comparison of the histological changes in the skin of DBA/2 and C57BL/6 mice following exposure to various promoting agents. Carcinogenesis 1987;8:1807-15.
15. Peto R, Pike MC, Day NE, et al. Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. IARC Monogr Eval Carcinog Risk Chem Hum Suppl 1980;2 Suppl:311-426.
16. Ewing MW, Conti CJ, Kruszewski FH, Slaga TJ, DiGiovanni J. Tumor progression in Sencar mouse skin as a function of initiator dose and promoter dose, duration, and type. Cancer Res 1988;48:7048-54.
17. DiGiovanni J, Bol DK, Wilker E, et al. Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion. Cancer Res 2000;60:1561-70.
18. Bol DK, Kiguchi K, Gimenez-Conti I, Rupp T, DiGiovanni J. Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice. Oncogene 1997;14:1725-34.
19. Wang XJ, Greenhalgh DA, Eckhardt JN, Rothnagel JA, Roop DR. Epidermal expression of transforming growth factor-α in transgenic mice: induction of spontaneous and 12-O-tetradecanoylphorbol-13-acetate-induced papillomas via a mechanism independent of Ha-ras activation or overexpression. Mol Carcinog 1994;10:15-22.
20. Vassar R, Fuchs E. Transgenic mice provide new insights into the role of TGF-α during epidermal development and differentiation. Genes Dev 1991;5:714-27.
21. Naito M, DiGiovanni J. Genetic background and development of skin tumors. Carcinog Compr Surv 1989;11:187-212.
22. Rodriguez-Puebla ML, Robles AI, Johnson DG, LaCava M, Conti CJ. Synchronized proliferation induced by 12-O-tetradecanoylphorbol-13- acetate treatment of mouse skin: an in vivo model for cell cycle regulation. Cell Growth Differ 1998;9:31-9.
23. Ramirez A, Bravo A, Jorcano JL, Vidal M. Sequences 5′ of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a lacZ gene in the adult and during development. Differentiation 1994;58:53-64.
24. Rodriguez-Puebla ML, LaCava M, Gimenez-Conti IB, Johnson DG, Conti CJ. Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin. Oncogene 1998;17:2251-8.
25. Balasubramanian S, Ahmad N, Jeedigunta S, Mukhtar H. Alterations in cell cycle regulation in mouse skin tumors. Biochem Biophys Res Commun 1998;243:744-8.
26. Balasubramanian S, Ahmad N, Mukhtar H. Upregulation of E2F transcription factors in chemically induced mouse skin tumors. Int J Oncol 1999;15:387-90.
27. Peng XD, Xu PZ, Chen ML, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003;17:1352-65.
28. Yang ZZ, Tschopp O, Di-Poi N, et al. Dosage-dependent effects of Akt1/protein kinase Bα (PKBα) and Akt3/PKBγ on thymus, skin, and cardiovascular and nervous system development in mice. Mol Cell Biol 2005;25:10407-18.
29. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B. Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 2002;10:721-33.
30. Hu CL, Cowan RG, Harman RM, Quirk SM. Cell cycle progression and activation of Akt kinase are required for insulin-like growth factor I-mediated suppression of apoptosis in granulosa cells. Mol Endocrinol 2004;18:326-38.
31. Shelton JG, Blalock WL, White ER, Steelman LS, McCubrey JA. Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. Cell Cycle 2004;3:503-12.
32. Rathmell JC, Elstrom RL, Cinalli RM, Thompson CB. Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. Eur J Immunol 2003;33:2223-32.
33. Kandel ES, Skeen J, Majewski N, et al. Activation of Akt/protein kinase B overcomes a G(2)/M cell cycle checkpoint induced by DNA damage. Mol Cell Biol 2002;22:7831-41.
34. Shioi T, McMullen JR, Kang PM, et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 2002;22:2799-809.
35. Matsui T, Li L, Wu JC, et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 2002;277:22896-901.
36. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 2001;21:2203-12.
37. Blanco-Aparicio C, Perez-Gallego L, Pequeno B, Leal JF, Renner O, Carnero A. Mice expressing myrAKT1 in the mammary gland developcarcinog en-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis 2007;28:584-94.
38. Malstrom S, Tili E, Kappes D, Ceci JD, Tsichlis PN. Tumor induction by a Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus. Proc Natl Acad Sci U S A 2001;98:14967-72.
39. Majumder PK, Yeh JJ, George DJ, et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A 2003;100:7841-6.
40. Ma X, Ziel-van der Made AC, Autar B, et al. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 2005;65:5730-9.
41. Suzuki A, Itami S, Ohishi M, et al. Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res 2003;63:674-81.